Table 7.
DEX implant in retinitis pigmentosa
| Reference | Study design | No of eyes | Previous treatment | Treatment | Follow-up | Retreatment | BCVA | CMT | Complications |
|---|---|---|---|---|---|---|---|---|---|
| Srour et al77 | Retrospective | 4 | CAIs in all cases subtenon TA 1 case NSAIDs in 2 cases |
DEX | 6 months | 2 DEX in 2 eyes after 3 months | From 20/160 to 6 months: 20/125 after 1 DEX | From 443±185 μm to 6 months: 305±124 μm after 1 DEX | None |
| Ahn et al78 | Case report | 2 eyes of one patient | CAIs Anti-VEGF IVT |
DEX | 12 months | 2 DEX in 1 eye 6 months after DEX | From 20/100 to 12 months: 20/60 RE From 20/150 to 12 months: 20/100 LE |
From 631 μm to 12 months: 531 μm RE From 681 μm to 12 months: 499 μm LE |
IOP rise IOP>21 mmHg |
| Saatci et al79 | Case report | 2 eyes of one patient | Topical CAIs | 1 DEX | 7 months | NR | From 2/10 to 1 week: 4/10 both eyes 3 months: 2/10 both eyes |
NR | None |
| Patil and Lotery80 | Case report | 1 | Topical CAIs Depo-Medrone Parabulbar Anti-VEGF IVT IVTA Cryotherapy |
1 DEX | 10 months | NR | From 1.01 logMAR to 6 weeks: 0.89 logMAR | From 559 μm to 6 weeks: 271 μm | None |
Abbreviations: BCVA, best corrected visual acuity; CAIs, carbonic anhydrase inhibitors; CMT, central macular thickness; DEX, dexamethasone implant; IOP, intraocular pressure; IVT, intravitreal; IVTA, intravitreal triamcinolone; LE, left eye; NR, not reported; NSAIDs, nonsteroidal anti-inflammatory drugs; RE, right eye; TA, triamcinolone acetonide; VEGF, vascular endothelial growth factor.